Aethlon Medical, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2023 (fiscal Q2 and first half of fiscal 2024). Filed November 14, 2023. The company is a clinical-stage medical device developer; the filing reports no revenue.
Financial performance and position
| Metric | Three months ended September 30, 2023 | Six months ended September 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | None reported | ||
| Operating expenses | $3.18 million | $6.58 million | $3.67 million and $6.57 million |
| Operating loss | $3.18 million | $6.58 million | $3.67 million and $6.57 million |
| Net loss | $3.03 million | $6.32 million | $3.81 million and $6.72 million |
| Basic and diluted loss per share | $1.22 | $2.57 | $1.84 and $3.70 |
| Net cash used in operating activities | $5.19 million | $5.61 million |
Operating expenses were essentially flat year over year for the six-month period, while quarterly expenses declined 13.4%. Lower general and administrative costs, including reduced COVID-19 trial and manufacturing-related spending, were partly offset by higher professional fees and payroll. Interest and other income was $266,871 for the six months, compared with none in 2022. No operating revenue or meaningful profit margins were reported.
At September 30, 2023, cash was $10.18 million, working capital was $8.78 million, total assets were $12.83 million, and total liabilities were $2.51 million. Cash declined from $14.53 million at March 31, 2023. Liabilities included $1.08 million of lease obligations; the filing reports no borrowings. Cash and restricted cash totaled $10.26 million. The company reported a six-month net decrease in cash and restricted cash of $4.36 million.
Changes, outlook, and risks
- Management said existing cash at September 30 was expected to fund operations for at least 12 months from the financial statements’ issuance date. It also expects continued losses and negative cash flows and says it will need additional capital; future clinical-trial spending is expected to increase.
- The company raised $1.09 million net through its at-the-market (ATM) program during the six months; no ATM capital was raised in the quarter. The filing describes potential equity financing, which could dilute shareholders.
- The Hemopurifier is an investigational device with FDA Breakthrough Device designations for certain cancer and viral-disease indications; these designations are not FDA marketing approval. Australia oncology trial preparations were underway. India granted clearance in October 2023 for a Phase 1 solid-tumor trial, subject to additional study and ethics approvals. COVID-19 studies and manufacturing qualification remain relevant program developments.
- U.S. manufacturing supply remains dependent on FDA qualification of suppliers and final testing. The company expected its first manufacturing lot using its original GNA supplier to be approved and released by the end of December 2023. It stated that devices on hand were sufficient for planned Australia and India oncology trials.
- After quarter-end, the company effected a 1-for-10 reverse stock split on October 4, 2023. On November 7, CFO James B. Frakes became interim CEO while retaining the CFO role; Guy Cipriani became COO.
- Key risks include continued losses and financing needs, clinical and regulatory uncertainty, supplier and manufacturing delays, potential Nasdaq listing compliance issues, competition and intellectual-property protection. Management reported effective disclosure controls and no material changes in internal control over financial reporting. No pending or threatened legal proceedings were reported.
Investor verification priorities
- Reconcile the filing’s share-sale disclosures: the financial statements report 177,891 ATM shares at an average $6.11, while MD&A reports 1,778,901 shares at $0.61. The 1-for-10 reverse split may explain the presentation difference; confirm the adjusted share count and offering capacity.
- Check the stated cash runway against actual cash use, upcoming trial and manufacturing costs, and the company’s ability to obtain further financing.
- Track FDA supplier qualification, manufacturing-lot release, and the timing and required approvals for planned clinical trials.
- Note that the MD&A labels comprehensive-loss figures ($3.04 million quarterly and $6.32 million for six months) as net loss in places; the statements of operations report net losses of $3.03 million and $6.32 million, respectively.
- Confirm post-split share count and Nasdaq listing compliance, as well as any subsequent changes to management, financing, or trial plans.